Cargando…

Synthetic Cell-Based Immunotherapies for Neurologic Diseases

The therapeutic success and widespread approval of genetically engineered T cells for a variety of hematologic malignancies spurred the development of synthetic cell-based immunotherapies for CNS lymphoma, primary brain tumors, and a growing spectrum of nononcologic disease conditions of the nervous...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Baumgarten, Louisa, Stauss, Hans J., Lünemann, Jan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474853/ https://www.ncbi.nlm.nih.gov/pubmed/37385738 http://dx.doi.org/10.1212/NXI.0000000000200139

Ejemplares similares

Neonatal Fc Receptor–Targeted Therapies in Neurology
por: Nelke, Christopher, et al.
Publicado: (2022)

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Neurology of cancer immunotherapy
por: De Grado, Amedeo, et al.
Publicado: (2022)

Neurologic Complications of Cancer Immunotherapy
por: Alsalem, Aseel N., et al.
Publicado: (2023)

Impact of Hydrophilic Modification of Synthetic Dialysis Membranes on Hemocompatibility and Performance
por: Zawada, Adam M., et al.
Publicado: (2022)

Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy
por: Pachmayr, Ludwig O., et al.
Publicado: (2023)

Engineering CD4+ T Cells to Enhance Cancer Immunity
por: Sillito, Francesca, et al.
Publicado: (2020)

Toward the development of true “off‐the‐shelf” synthetic T‐cell immunotherapy
por: Iriguchi, Shoichi, et al.
Publicado: (2019)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
por: Dalakas, Marinos C., et al.
Publicado: (2022)

Synthetic immunology: T-cell engineering and adoptive immunotherapy
por: Si, Wen, et al.
Publicado: (2018)

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
por: Korsukewitz, Catharina, et al.
Publicado: (2020)

Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy
por: Bonfá, Giuliano, et al.
Publicado: (2020)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

RNA-based therapeutics for neurological diseases
por: Anthony, Karen
Publicado: (2022)

Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma
por: Winograd, Evan, et al.
Publicado: (2021)

Improving TCR Gene Therapy for Treatment of Haematological Malignancies
por: Nicholson, Emma, et al.
Publicado: (2012)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Human Endogenous Retroviruses in Neurological Diseases
por: Küry, Patrick, et al.
Publicado: (2018)

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
por: Chung, Christopher, et al.
Publicado: (2023)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Cardiolipin, Mitochondria, and Neurological Disease
por: Falabella, Micol, et al.
Publicado: (2021)

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
por: Keller, Christian W., et al.
Publicado: (2021)

Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma
por: Birnbaum, Tobias, et al.
Publicado: (2013)

Turn to TCRs when CARs fail
por: Stauss, Hans J.
Publicado: (2017)

Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
por: Yousaf, Muhammad, et al.
Publicado: (2022)

Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy
por: Park, Kyong‐Su, et al.
Publicado: (2021)

DNA Testing in Neurologic Diseases
por: O'Brien, D.P., et al.
Publicado: (2014)

Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy
por: Raskov, Hans, et al.
Publicado: (2020)

Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential
por: Keller, Christian W., et al.
Publicado: (2017)

COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
por: Marsh, Elisabeth B., et al.
Publicado: (2021)

Vaccination and immunotherapies in neuroimmunological diseases
por: Winkelmann, Alexander, et al.
Publicado: (2022)

Carriers in Cell-Based Therapies for Neurological Disorders
por: Wong, Francisca S. Y., et al.
Publicado: (2014)

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
por: Flingai, Seleeke, et al.
Publicado: (2015)

Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Zebrafish: An in vivo model for the study of neurological diseases
por: Best, J D, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_sclguhhean0hm423a78i3fg0es